Assessing whether a highly absorbable curcumin formulation can decrease inflammation and free radical damage in middle aged participants

Phase 2

• Conditions: subclinical inflammation; oxidative damage; Inflammatory and immune system; Alternative and Complementary Medicine - Other alternative and complementary medicine; Inflammatory and Immune System - Normal development and function of the immune system

• Registration Number: ACTRN12620000868987
• Lead Sponsor: Australasian Research Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-08-31
• Last Update Posted: 7 September 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Participants recruited into this study will be males and/or females aged between 40 and 60 years who:
•are not currently taking any pharmacotherapies for inflammatory disorders including, rheumatoid arthritis and other autoimmune conditions including, Lupus, MS, Guillian-Barre syndrome, psoriasis etc.
•do not have impaired renal function,
•do not regularly take aspirin, ibuprofen or other anti-inflammatory medications,
•are willing to cease supplementation(e.g. antioxidants, flavonoids, minerals, omega-3 etc) for at least 7 days before the start of this study, and are willing to refrain from taking additional supplements for the duration of the trial,
•have no known sensitivity to turmeric, curcumin or its metabolites, or red/yellow food colouring,
•have an hsCRP between 2.5 – 10.00 µg/mL,
•are not pregnant

Exclusion Criteria

- Are currently taking anti-inflammatory medication
- Are cognitively impaired and/or are unable to give informed consent for any reason

Study & Design

• Study Type: Interventional
• Study Design: Not specified